659 



ARNOLD Sc PORTER 



The Honorable Henry A. Waxman, Chairman 

 The Honorable Thomas J. Bliley, Jr. 

 September 28, 1994 

 Page 2 



of Psychiatry, Tufts University School of Medicine. 

 These statements are contained in Volume 2 . of the six- 

 volume submission that Philip Morris made to the FDA's 

 Drug Abuse Advisory Committee in connection with that 

 Committee's meeting on August 2, 1994. As you )cnow, the 

 Advisory Committee addressed "issues related to nicotine 

 and smoking, including the relationship between nicotine 

 dose and addiction in smokers." 59 Fed. Reg. 35738 

 (July 13, 1994) . 



Second, also enclosed in response to your 

 request, are the remaining volumes of the six-volume set 

 submitted to the Advisory Committee. As you will note, 

 Volume 1.0 is the statement submitted by Philip Morris 

 and American Tobacco regarding the issues considered at 

 the Advisory Committee's August 2 meeting. It includes 

 numerous citations, the texts of which can be found in 

 Volumes 3.1, 3.2, 3.3 and 3.4. Because the Volume 3 set 

 constitutes about 1,500 pages in length, we have 

 provided copies only to you, and not to all Subcommittee 

 Members. However, we would be happy, upon request, to 

 provide copies to any Subcommittee Member. 



Finally, we refer you to the enclosed excerpts 

 from the transcript of the August 2 Advisory Committee 

 meeting, which are statements of three witnesses who 

 testified in general agreement with the views expressed 

 by Dr. Ellis. Two of these are Doctors Bozarth and 

 Ciraulo, whose credentials are described above, and the 

 other is Dr. John Robinson of the R. J. Reynolds tobacco 

 company. 



We trust that the enclosed materials respond to 

 your inquiry. 



Sincerely, 



Peter T. Grossi, Jr. 

 Enclosures 



cc: Members of the Subcommittee on 

 Health and the Envii;-onment 



